Conditions: HIV Infections HSV-2 Genital Herpes
Keywords: Prevention
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: yes

Brief summary:
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.

Detailed description:

Arms:
arm 1: 3%w/w SPL7013 vaginal gel (VivaGel)

Interventions: intervention 1: 3% SPL7013 Gel (VivaGel)
Intervention descriptions: intervention 1: A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.

Protocol document: